Recombinant Human IL-13 (carrier-free) 571104 from BioLegend

Product Specs
ItemRecombinant Human IL-13 (carrier-free)
CompanyBioLegend
Price $464.00Supplier Page View Company Product Page
Catalog Number571104
Size25 µg
Format0.22 µm filtered protein solution is in 10 mM Sodium Phosphate buffer, 150 mM NaCl, pH 7.2
ApplicationsBioassay
Concentration10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool
SpeciesHuman
Gene Nameinterleukin 13
NCBI Gene AliasesIL-13, P600
NCBI Full Gene Nameinterleukin 13
Molecule NameIL-13

Add to Compare List

BioLegend

8999 BioLegend Way

San Diego, California 92121

United States

Phone: 1-877-246-5343 Toll-Free, USA & Canada
1-858-768-5800 International
Fax: 1-877-455-9587

Company Profile

Website: biolegend.com

(1) IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancerMolecular Therapy AdvancesJune 11, 2026Lupita S. Lopez, Ziyou Cui, Yukiko Yamaguchi, John P. Murad, Zhiyuan Yang, Ke Zou, Jason Yang, Wen-Chung Chang, Stephen J. Forman, Vivien W. Chan, et al.changed once after 3–5 days to media containing M-CSF, IL-4 (BioLegend, 574004), IL-13 (BioLegend, 571102), and IL-6. All cytokines and LPS were used at 20 ng/mL. After differentiation, macrophages were lifted

(2) Bifidobacterium animalis subsp. Lactis BX-BC08 modulates gut microbiota and secretes alpha-Ketoglutaric acid to alleviate MC903-induced atopic dermatitisJournal of translational medicineJuly 10, 2025Zhao J, Kui L, Huang J, Deng J, Liu L, Zhu C, Shi Y, Li C, Xiao Y, Yu J, et al.PCS-200-010, ATCC) were treated with recombinant human IL-4 (20 ng/ml; 574002, BioLegend) and IL-13 (10 ng/ml; 571102, BioLegend), with or without AKG, for 24 h. Following treatment, RNA was extracted to assess the expression

(3) mTOR signaling regulates the development of airway mucous cell metaplasia associated with severe asthmaJCI InsightJuly 8, 2025Katrina M. Kudrna, Luis F. Vilches, Evan M. Eilers, Shailendra K. Maurya, Steven L. Brody, Amjad Horani, Kristina L. Bailey, Todd A. Wyatt, John D. Dickinsondifferentiation (ALI days 21–28), hAEC were treated with human recombinant IL-13 (10 ng/mL) (BioLegend, 571102) and/or rapamycin (250 nM, 1 μM) (MilliporeSigma, 553210) for the indicated times. Approval of clinical

(4) Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumorsProceedings of the National Academy of SciencesJune 3, 2025Derrick Broka, Shoshana Klein, Alexei Shir, Babette Schade, Meera Saxena, Athanasia Dasargyri, Anita Jarzebinska, Caroline De Feyter, Davor Bajic, David Colecchia, et al.were polarized to M2 phenotype with IL-4 (BioLegend, Cat no. 574004) and IL-13 (BioLegend, Cat no. 571102) for 24 h. The medium was then replaced by fresh medium lacking the M2 polarization factors and the

(5) M2a Macrophage-Dominant Microenvironment in Inflammation Attenuation and Wound Healing of Human Corneal Endothelial CellsInvestigative ophthalmology & visual scienceJune 2, 2025Lee SH, Koh A, Lee SJ, Lee H, Kim KW.macrophage polarization. Recombinant human IL-4 (#574004, 20 ng/mL; BioLegend) and recombinant human IL-13 (#571104, 20 ng/mL; BioLegend) were treated for 24 hours for M2a macrophage polarization. Co-Culture of M2a

(6) CD105+ fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiationBreast Cancer ResMay 15, 2025Eric G. Carlson, Jennifer C. Lopez, Yukiko Yamaguchi, Jackson Gibson, Saul J. Priceman, Mark A. LaBargewas changed once after 4 days to media containing M-CSF, IL-4 (BioLegend, 574,002), IL-13 (BioLegend, 571102) and IL-6. All cytokines and LPS were used at 20 ng/mL. After another 4 days of differentiation, macrophages

(7) Engineered CD147-CAR macrophages for enhanced phagocytosis of cancersCancer Immunology, ImmunotherapyJuly 2, 2024Koollawat Chupradit, Saitong Muneekaew, Methichit WattanapanitchRPMI-1640 medium supplemented with 25 ng/mL IL-4 (Biolegend, 574008) and 25 ng/mL IL-13 (Biolegend, 571102). The cells were further cultured for 72 h. Afterward, the cells were harvested for flow cytometric analysis

(8) M2 macrophages participate in ILC2 activation induced by Helicobacter pylori infectionGut microbesJanuary 1, 2024Peng R, Xu C, Zhang L, Liu X, Peng D, Chen X, Liu D, Li R.were analyzed by flow cytometry (data not shown). IL-4 (Biolegend, #574006) and IL-13 (Biolegend, #571106) were added to the cell culture medium (10 ng/ml, 48 h). The M1 macrophages (CD11b+CD86+) and M2 macrophages

(9) Characterization of Neisseria gonorrhoeae colonization of macrophages under distinct polarization states and nutrients environmentFrontiers in cellular and infection microbiologyJanuary 1, 2024Juárez Rodríguez MD, Marquette M, Youngblood R, Dhungel N, Torres Escobar A, Ivanov SS, Dragoi AM.M1 polarization or 25 ng/ml IL-4 (BioLegend catalog #766202) and 25 ng/ml IL-13 (BioLegend catalog #571102) for M2 polarization. Primary human PBMC were differentiated into macrophages (hMDMs) after culturing

(10) JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of KeratinocytesInternational journal of molecular sciencesMay 25, 2023Arnold KA, Peterson LF, Beck LA, Brewer MG.(Invitrogen/Gibco, Grand Island, NY, USA). 4.2. Cytokines and JAKi IL-4, IL-13, IL-22, and IFNγ (Cat No.: 574004, 571104, 571304, 570204, respectively) were purchased from Biolegend (San Diego, CA, USA, and IL-17A (Cat No.:

(11) Isolation and Expansion of Primary Conjunctival Stem Cells (CjSCs) from Human and Rabbit TissuesBio-protocolDecember 20, 2022Zhong Z, Chen S.

(12) Supply Chain Disruptions During COVID-19 Pandemic Uncover Differences in Keratinocyte Culture MediaJID InnovNovember 1, 2022Moran MC, Pope EM, Brewer MG, Beck LA.differentiation and exposure to type 2 cytokines IL-4 and IL-13 at 50 ng/ml of each (number 574004 and 571104, BioLegend, San Diego, CA) or type 3 cytokine IL-17A (317ILB, R&D Systems, Minneapolis, MN). To measure

(13) PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophagesJournal for immunotherapy of cancerJune 1, 2022Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, et al.changed once after 3–5 days to media containing M-CSF, IL-4 (BioLegend, 574004), IL-13 (BioLegend, 571102) and IL-6. All cytokines and LPS were used at 20 ng/mL. After differentiation, macrophages were lifted

(14) CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1Scientific reportsJuly 21, 2021Durlanik S, Fundel-Clemens K, Viollet C, Huber HJ, Lenter M, Kitt K, Pflanz S.following stimuli were added to the culture: 20 ng/ml LPS (tlrl-b5lps, InvivoGen) + 50 ng/ml IFNγ (571104, BioLegend); 10 ng/ml IFNα (11100-1, PBL); 20 ng/ml IL-4 (130-093-922, Miltenyi Biotec) + 20 ng/ml IL-13

(15) Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical FunctionImmunitySeptember 15, 2020Gruber CN, Calis JJA, Buta S, Evrony G, Martin JC, Uhl SA, Caron R, Jarchin L, Dunkin D, Phelps R, et al.560701 Recombinant Human IL-6,BioLegend,Cat No. 570802 Recombinant Human IL-13,BioLegend,Cat No. 571102 Recombinant Human IL-21,BioLegend,Cat No. 571202 Recombinant Human Interferon Gamma,BioLegend,Cat

(16) Comparative Effects of Graphene and Molybdenum Disulfide on Human Macrophage ToxicitySmall (Weinheim an der Bergstrasse, Germany)September 1, 2020Lin H, Ji DK, Lucherelli MA, Reina G, Ippolito S, Samorì P, Bianco A.(Biolegend, #570204) to M1 macrophages and 20 ng/mL IL-4 (Peprotech, #200-04) and 20 ng/mL IL-13 (Biolegend, #571102) to M2 macrophages. Cells were cultured in RPMI (Lonza) supplemented with 10% heat-inactivated fetal

(17) SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across TissuesCellMay 28, 2020Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, et al.at increasing doses (0, 0.1, 0.5, 1, 5, 10 ng/mL) of human IL-4 (Biolegend 574004), IL-13 (Biolegend 571104), IFNα (Biolegend 592704), IFNγ (Biolegend 570204), IL-17A (Biolegend 570504), or IL-1β (Biolegend 579404)

(18) SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture modelsPloS oneJanuary 1, 2020Brasil da Costa FH, Lewis MS, Truong A, Carson DD, Farach-Carson MC.

(19) Apolipoprotein E is a concentration-dependent pulmonary danger signal that activates the NLRP3 inflammasome and IL-1β secretion by bronchoalveolar fluid macrophages from asthmatic subjectsThe Journal of allergy and clinical immunologyAugust 1, 2019Gordon EM, Yao X, Xu H, Karkowsky W, Kaler M, Kalchiem-Dekel O, Barochia AV, Gao M, Keeran KJ, Jeffries KR, et al.units (EU) per microgram of HDM protein. Recombinant human IFN-γ(# 570204), TNF-α(# 570104), IL-13 (# 571104), IL-17A (# 570504), and M-CSF (# 574806) were from BioLegend (San Diego, CA). Poly (I:C) (# tlrl-pic)

(20) Allergic inflammatory memory in human respiratory epithelial progenitor cellsNatureAugust 1, 2018Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C, Wadsworth MH 2nd, Hughes TK, Kazer SW, Yoshimoto E, et al.hours overnight at increasing doses (0, 0.1, 1, 10 ng/mL) of IL-4 (Biolegend 766205), IL-13 (Biolegend 571104), and (0.1, ng/mL) IL-4+IL-13 in combination (n=32 samples non-polyp and n=32 samples polyp basal cells

Be the First to Write a Review!

Journal of translational medicine

Recombinant Human IL-13 (carrier-free) from BioLegend

Description

BioLegend

Citations (22)

Reviews

Recombinant Human IL-13 (carrier-free) from BioLegend

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map